Mitochondrial dysfunction in antiphospholipid syndrome: Implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment

Blood

Volumn 119, Issue 24, 2012, Pages 5859-5870

  Perez Sanchez, Carlos ^a   Ruiz Limon, Patricia ^a   Aguirre, Maria Angeles ^a   Bertolaccini, Maria Laura ^b   Khamashta, Munther A ^c   Rodriguez Ariza, Antonio ^a   Segui, Pedro ^a   Collantes Estevez, Eduardo ^a   Barbarroja, Nuria ^d   Khraiwesh, Husam ^e   Gonzalez Reyes, Jose Antonio ^e   Villalba, Jose Manuel ^e   Velasco, Francisco ^a   Cuadrado, Maria Jose ^c   Lopez Pedrera, Chary ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Rayne Institute   (United Kingdom)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; SUPEROXIDE; TRANSCRIPTION FACTOR NRF2; UBIDECARENONE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPLEMENTATION;

EID: 84862496402     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-400986     Document Type: Article

References (50)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997;40(5):834-841.
3. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induced monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006;54(1):301-311.
4. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008;118(10):3453-3461.
5. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease activated receptors in monocytes from patients with primary Antiphospholipid syndrome. Arthritis Rheum. 2010;62(3):869-877.
6. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25(1):47-56. (Pubitemid 40054253)
7. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost. 2006;4(11):2461-2469.
8. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, et al. NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost. 2002;88(5):851-857. (Pubitemid 35345346)
9. Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum. 2004;50(9):2911-2919. (Pubitemid 39209530)
10. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene y monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol. 2004;16(11):1633-1641. (Pubitemid 39480782)
11. Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci. 2007;1108:540-553. (Pubitemid 47528768)
12. Soltész P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus. 2003;12(4):302-307.
13. Jiménez S, García-Criado MA, Tassies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology. 2005;44(6):756-761.
14. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of beta2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107(3):569-573. (Pubitemid 27102148)
15. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus. 1996;5(5):442-447. (Pubitemid 26354063)
16. Veres K, Lakos G, Kerenyi A, et al; Antiphospholipid antibodies in acute coronary syndrome. Lupus. 2004;13(6):423-427. (Pubitemid 38931773)
17. Cugno M, Borghi MO, Lonati LM, et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun. 2010;34(2):105-110.
18. Ames PRJ, Antionolfi I, Scenna G, Gaeta G, Margagliones M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost. 2009;7(4):537-542.
19. Perl A. Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity. 2010;43(1):1-6.
20. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep. 2003;5(5):383-390.
21. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol. 1996;51(1):1-9.
22. Iuliano L, Practico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood. 1997;90(10):3931-3935. (Pubitemid 27484045)
23. Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA. 2009;302(11):1210-1217.
24. Delgado Alves J, Mason LJ, Ames PR, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology. 2005;44(10):1238-1244. (Pubitemid 41487956)
25. Ames PR, Matsuura E, Batuca JR, et al. High density lipoprotein inversely related to its specific autoantibody favouring oxidation in thrombotic primary antiphospholipid syndrome. Lupus. 2010;19(6):711-716.
26. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660(1-2):171-199. (Pubitemid 38125244)
27. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition. 2010;26(3):250-254.
28. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ. Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs. 2010;19(4):535-554.
29. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185-1190.
30. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1):75-80. (Pubitemid 46112808)
31. Sato T. A modified method for lead staining of thin sections. J Electron Microsc (Tokyo). 1968;17(2):158-159.
32. Weibel ER. Stereological methods. Vol 1. Practical Methods for Biological Morphometry. New York, NY: Academic Press; 1979:26-46.
33. Weibel ER, Bolender RP. Stereological techniques for electron microscopic morphometry. In: Hayat MA, ed. Principles and Techniques of Electron Microscopy, Vol 3. New York, NY: Van Nostrand Rheinhold Company; 1973:237-296.
34. Liesa M, Palacin M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009;89(3):799-845.
35. Ong S-B, Hausenloy DJ. Mitochondrial morphology and cardiovascular disease. Cardiovasc Res. 2010;88(1):16-29.
36. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109(2):422-430. (Pubitemid 46105935)
37. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002;11(4):208-214. (Pubitemid 34506724)
38. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64(2):315-317. (Pubitemid 40193636)
39. Margarita A, Batuca J, Scenna G, et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci. 2007;1108:475-480. (Pubitemid 47528761)
40. Shah D, Wanchu A, Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiol. 2011;216(9):1010-1017.
41. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338(7):436-445. (Pubitemid 28135672)
42. Marutsuka K, Hatakeyama K, Yamashita A, Asada Y. Role of thrombogenic factors in the development of atherosclerosis. J Atheroscler Thromb. 2005;12(1):1-8.
43. Perricone C, De Carolis C, Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev. 2009;8(8):697-701.
44. Yang H, Magilnick N, Lee C, et al. Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol Cell Biol. 2005;25(14):5933-5946. (Pubitemid 40949988)
45. Chan JY, Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta. 2000;1517(1):19-26.
46. Ortona E, Margutti P, Matarrese P, Franconi F, Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev. 2008;7(7):579-584.
47. Shah D, Kiran R, Wanchu A, Bhatnagar A. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett. 2010;129(1):7-12.
48. Zhang Q, Ye DQ, Chen GP, Zheng Y. Oxidative protein damage and antioxidant status in systemic lupus erythematosus. Clin Exp Dermatol. 2010;35(3):287-294.
49. Simoncini S, Sapet C, Camoin-Jau L, et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with antiphospholipid syndrome. Int Immunol. 2005;17(4):489-500. (Pubitemid 40568124)
50. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121(18):2012-2022.